FDA Outlines Regulatory Framework for AI in Medical Products
March 15, 2024
The FDA has published a comprehensive plan to regulate artificial intelligence (AI) in medical products, marking a significant step in addressing the increasing integration of AI technologies in the healthcare sector. This collaborative report, spanning various FDA centers, underscores the agency’s commitment to fostering the ethical development and use of AI, ensuring the safety and effectiveness of medical products enhanced by this technology. With over 300 AI-related drug submissions since 1995, the FDA’s initiatives aim to educate stakeholders, mitigate algorithmic bias, and adapt to evolving clinical contexts. The plan includes:
- Drafting guidance for AI in regulatory decision-making.
- Finalizing marketing submission protocols for AI-driven devices.
- Considering lifecycle management for AI software in medical devices.
The FDA’s efforts to bolster its AI expertise reflect the growing importance of AI in curating medical data and the need for specialized knowledge in regulatory processes.
To read more, click here.
[Source: Endpoints, March 15th, 2024]
